Cardiac autoantibodies in dilated cardiomyopathy become undetectable with disease progression.
about
Presence of circulating anti-myosin antibodies in endomyocardial fibrosisCirculating autoantibodies to troponin I in Emery-Dreifuss muscular dystrophyCirculating cardiac autoantibodies in dilated cardiomyopathy and myocarditis: pathogenetic and clinical significance.Autoantibodies and cardiovascular dysfunction: cause or consequence?β1-Adrenoceptor autoantibodies from DCM patients enhance the proliferation of T lymphocytes through the β1-AR/cAMP/PKA and p38 MAPK pathways.The transition from viral to autoimmune myocarditis.Consequences of unlocking the cardiac myosin molecule in human myocarditis and cardiomyopathiesCeliac disease with pulmonary haemosiderosis and cardiomyopathy.Localization of CD8 T cell epitope within cardiac myosin heavy chain-α334-352 that induces autoimmune myocarditis in A/J miceImmunomodulatory effects of mesenchymal stromal cells revisited in the context of inflammatory cardiomyopathy.Clinical implications of anti-heart autoantibodies in myocarditis and dilated cardiomyopathy.Autoimmune markers are undetectable in end stage idiopathic dilated cardiomyopathy.The clinical and diagnostic significance of anti-myosin autoantibodies in cardiac disease.Immune-mediated and autoimmune myocarditis: clinical presentation, diagnosis and management.Elevated serum levels of soluble interleukin-2 receptor, neopterin and beta-2-microglobulin in idiopathic dilated cardiomyopathy: relation to disease severity and autoimmune pathogenesis.Sera from patients with idiopathic dilated cardiomyopathy decrease ICa in cardiomyocytes isolated from rabbits.Serum anti-p53 antibodies do not occur in patients with heart failure due to idiopathic dilated and ischemic cardiomyopathies.
P2860
Q28473727-2816D3CF-B81E-42F0-BCD8-4A062FED2552Q33810299-4433BBE7-8D2A-46F7-A592-0887A4F9E2F2Q33960727-CF2A8CA5-9403-4DC5-9033-D3A18F1D4C05Q34473885-10E599DE-F5A6-421B-9A77-BB68E78A7535Q34541400-B7AF03B8-5FED-4212-AD14-4C85C8B02542Q34574056-80431255-6E71-42EA-8FEA-20394CC9A479Q35026108-1DD90B91-EC20-4856-9326-26C312E67E7CQ35978536-15E435C2-7DA9-407D-ABC2-839A79359028Q36307488-55CD4913-77EB-4897-8E3F-E981924C87C5Q36990126-4B89B545-C0C5-4859-85F0-9101B255FCD2Q37051232-078CD6DF-CA30-4F48-9311-50BD396210CDQ37241395-975A6C4A-C499-43DD-8BA3-8F94D4580B61Q37826114-4F4188DD-4614-4C86-958D-C6CF36FDA610Q38056870-E0837452-B152-46C9-9518-016440505915Q43540799-607BB513-53E2-4724-B254-0BCDE350DF58Q44980684-171EA15A-8737-4520-964D-7610DCF9AB5CQ53641703-4B0B7EF6-1152-4A42-B112-8CAA78A1FD83
P2860
Cardiac autoantibodies in dilated cardiomyopathy become undetectable with disease progression.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
1997年论文
@zh
1997年论文
@zh-cn
name
Cardiac autoantibodies in dila ...... able with disease progression.
@en
type
label
Cardiac autoantibodies in dila ...... able with disease progression.
@en
prefLabel
Cardiac autoantibodies in dila ...... able with disease progression.
@en
P2093
P2860
P356
P1433
P1476
Cardiac autoantibodies in dila ...... able with disease progression.
@en
P2093
Caforio AL
Dalla Libera L
Goldman JH
Keeling PJ
McKenna WJ
P2860
P356
10.1136/HRT.77.1.62
P407
P577
1997-01-01T00:00:00Z